We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ILLUCCIX Configuration A kit for the preparation of gallium Ga 68 gozetotide 25mcg injection vial (USA)
Section 19A approved medicine
ILLUCCIX Configuration A kit for the preparation of gallium Ga 68 gozetotide 25mcg injection vial (USA)
Section 19A approval holder
Telix Pharmaceuticals (ANZ) Pty Ltd ABN 20 620 871 730
Phone
03 9093 3880
Approved until
Status
Current
Medicines in short supply/unavailable
ILLUCCIX Configuration A Kit for the Preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC 25 mcg solution for injection Glass Vial - ARTG 356332
Indication(s)
ILLUCCIX, after radiolabelling with Ga-68, is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) imaging combined with Computerised Tomography (CT) in patients with prostate cancer:
- who are at risk of metastasis and who are suitable for initial definitive therapy.
- who have suspected recurrence based on elevated serum prostate specific antigen (PSA) level.
- for the selection of patients with metastatic prostate cancer in whom lutetium Lu 177 vipivotide tetraxetan PSMA-directed therapy is indicated.
Images
